Acer Therapeutics Appoints Dr. William T. Andrews as Chief Medical Officer
October 05 2017 - 7:30AM
Acer Therapeutics Inc., (Nasdaq:ACER), a pharmaceutical company
focused on the acquisition, development and commercialization of
therapies for serious rare and ultra-rare diseases with critical
unmet medical need, today announced the appointment of William T.
Andrews, M.D., FACP as Chief Medical Officer of the Company to
succeed Robert D. Steiner, M.D. in that position.
“We are pleased to welcome Dr. Andrews to the
executive management team, as we continue to successfully and
rapidly advance our lead product candidate, EDSIVO™, a potential
life-saving therapy for patients with vEDS,” said Chris Schelling,
CEO and Founder of Acer. “Dr. Andrews brings tremendous experience
to this role and will be instrumental in preparing our NDA
submission of EDSIVO™, which we expect to accomplish in the first
half of 2018, and we look forward to his guidance in the medical
marketplace as we plan for our next steps. We thank Dr. Steiner for
his significant contributions to Acer during a critical time in the
Company’s growth.”
About William T. Andrews, M.D., FACPDr. Andrews
joins Acer Therapeutics as Chief Medical Officer after having
worked in the biotech/pharmaceutical industry for 17 years in both
Clinical Development and Medical Affairs in multiple therapeutic
areas, with a focus and extensive experience in rare
diseases. Dr. Andrews has significant medical marketplace and
product launch experience, having served as the medical lead for
six product launches, including Xopenex HFA®, Brovana®, Alvesco®,
Omnaris®, Catena®, and Juxtapid®. Most recently, he provided
strategic consulting services to rare disease companies in Clinical
Development, Medical Affairs, Go-To-Market/Launch planning, and
Business Development/Corporate Strategy. Previously, Dr. Andrews
held senior leadership positions and positions of increasing
responsibility at Aegerion Pharmaceuticals, Santhera
Pharmaceuticals, Sepracor, and ClinQuest. He received his
undergraduate degree in Biology from Harvard University and his
M.D. degree from Yale University School of Medicine. Dr. Andrews
practiced medicine for 7 years full-time and 11 years part-time in
the Boston area as a board-certified Internist and an Attending
Physician at Brigham and Women’s Hospital, and was on the Clinical
Faculty at Harvard Medical School.
About Acer TherapeuticsAcer,
headquartered in Cambridge, MA, is a pharmaceutical company focused
on the acquisition, development and commercialization of therapies
for patients with serious rare and ultra-rare diseases with
critical unmet medical need. Acer’s late-stage clinical pipeline
includes two candidates for severe genetic disorders for which
there are few or no FDA-approved treatments: EDSIVO™ (celiprolol)
for vEDS, and ACER-001 (a fully taste-masked, immediate release
formulation of sodium phenylbutyrate) for urea cycle disorders
(UCD) and Maple Syrup Urine Disease (MSUD). There are no
FDA-approved drugs for vEDS and MSUD and limited options for UCD,
which collectively impact more than 4,000 patients in the United
States. Acer’s products have clinical proof-of-concept and
mechanistic differentiation, and Acer intends to seek approval for
them in the U.S. by using the regulatory pathway established under
section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or
FFDCA, that allows an applicant to rely for approval at least in
part on third-party data, which is expected to expedite the
preparation, submission, and approval of a marketing
application.
For more information, visit www.acertx.com.
Forward-Looking StatementsThis
press release contains “forward-looking statements” that involve
substantial risks and uncertainties for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995.
All statements, other than statements of historical facts, included
in this press release regarding strategy, future operations, future
financial position, future revenue, projected expenses, prospects,
plans and objectives of management are forward-looking statements.
Examples of such statements include, but are not limited to,
statements relating to the potential for EDSIVO™ (celiprolol) and
ACER-001 to safely and effectively target diseases; the adequacy of
the company’s capital to support its future operations and its
ability to successfully initiate and complete clinical trials and
regulatory submissions; the nature, strategy and focus of the
company; and the development, expected timeline and
commercial potential of any product candidates of the company. Acer
may not actually achieve the plans, carry out the intentions or
meet the expectations or projections disclosed in the
forward-looking statements and you should not place undue reliance
on these forward-looking statements. Such statements are based on
management’s current expectations and involve risks and
uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation, risks
and uncertainties associated with the ability to project future
cash utilization and reserves needed for contingent future
liabilities and business operations, the availability of sufficient
resources of the company to meet its business objectives and
operational requirements, the fact that the results of earlier
studies and trials may not be predictive of future clinical trial
results, the protection and market exclusivity provided by Acer’s
intellectual property, risks related to the drug development and
the regulatory approval process and the impact of competitive
products and technological changes. Acer disclaims any intent or
obligation to update these forward-looking statements to reflect
events or circumstances that exist after the date on which they
were made. You should review additional disclosures we make in our
filings with the Securities and Exchange Commission, including our
Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K.
You may access these documents for no charge at
http://www.sec.gov.
Investor Contact:Hans VitzthumLifeSci
AdvisorsPh: 212-915-2568hans@lifescieadvisors.com
Acer Therapeutics (NASDAQ:ACER)
Historical Stock Chart
From Sep 2024 to Oct 2024
Acer Therapeutics (NASDAQ:ACER)
Historical Stock Chart
From Oct 2023 to Oct 2024